---
title: "Plasma biomarkers linked to longitudinal Alzheimer’s-related brain atrophy patterns"
id: "medrxiv-19-association-of-plasma-biomarkers-with-longitudinal-change-in-age-and-alzheimer"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-19-association-of-plasma-biomarkers-with-longitudinal-change-in-age-and-alzheimer"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.11.26362869v1?rss=1"
published_at: "2026-09-17T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Plasma biomarkers linked to longitudinal Alzheimer’s-related brain atrophy patterns
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-19-association-of-plasma-biomarkers-with-longitudinal-change-in-age-and-alzheimer
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.11.26362869v1?rss=1)
- **Published At:** 2026-09-17T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Study used data from the Baltimore Longitudinal Study of Aging (N=818) with plasma biomarker measurements obtained while participants were cognitively unimpaired. 2,293 MRI scans provided longitudinal brain atrophy data. - Plasma markers measured: **Aβ42/Aβ40** (Quanterix and Lumipulse assays), **GFAP**, **NfL**, **p-tau181**, and **p-tau217**. - During follow-up 104 participants converted to MCI/dementia: 74 due to Alzheimer disease (AD), 24 due to non-AD etiologies, and 6 of unknown etiology. - Conversion analyses: **p-tau181**, **p-tau217**, and Aβ42/Aβ40 (Lumipulse) were associated with incident MCI/dementia due to AD but not with non-AD causes; **GFAP** was associated with incident MCI/dementia due to both AD and non-AD etiologies. - Longitudinal atrophy analyses used multidimensional pattern scores: **SPARE-BA** (brain age), **SPARE-AD** (AD-like atrophy), and five R-indices representing dominant atrophy dimensions. All four core biomarkers (Aβ42/Aβ40, p-tau181, p-tau217, GFAP; NfL mentioned among measured) showed associations with longitudinal **SPARE-AD** change. - Regional associations: Aβ42/Aβ40 (both Quanterix and Lumipulse), **p-tau181**, and **p-tau217** linked to longitudinal parieto-temporal atrophy; **p-tau217** uniquely associated with medial temporal lobe atrophy over time. - No associations were found between plasma biomarkers and **SPARE-BA** or the R-indices that captured subcortical, diffuse cortical, or perisylvian atrophy patterns. - Conclusion: Among cognitively unimpaired individuals, **p-tau217** showed the strongest and most extensive associations with subsequent AD diagnosis and longitudinal AD-related brain atrophy. Details on effect sizes, confidence intervals, and some analytic specifics were not reported in the abstract.
## Clinical Analysis & Structured Key Points
Association of plasma biomarkers with longitudinal change in age- and Alzheimer's disease-related brain atrophy patterns | medRxiv Skip to main content Association of plasma biomarkers with longitudinal change in age- and Alzheimer's disease-related brain atrophy patterns View ORCID Profile Murat Bilgel , Ishaan Shah , Jasmine Cooper , Yang An , View ORCID Profile Keenan A Walker , Sara G Ho , View ORCID Profile Abhay R Moghekar , Zhijian Yang , View ORCID Profile Guray Erus , View ORCID Profile Christos Davatzikos , View ORCID Profile Luigi Ferrucci , View ORCID Profile Susan M Resnick doi: https://doi.org/10.64898/2026.09.11.26362869 Murat Bilgel 1 National Institute on Aging; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Murat Bilgel For correspondence: murat.bilgel{at}nih.gov Ishaan Shah 1 National Institute on Aging; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jasmine Cooper 1 National Institute on Aging; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yang An 1 National Institute on Aging; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Keenan A Walker 1 National Institute on Aging; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Keenan A Walker Sara G Ho 2 Johns Hopkins University School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abhay R Moghekar 2 Johns Hopkins University School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Abhay R Moghekar Zhijian Yang 3 University of Pennsylvania Find this author on Google Scholar Find this author on PubMed Search for this author on this site Guray Erus 3 University of Pennsylvania Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Guray Erus Christos Davatzikos 3 University of Pennsylvania Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Christos Davatzikos Luigi Ferrucci 1 National Institute on Aging; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Luigi Ferrucci Susan M Resnick 1 National Institute on Aging; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Susan M Resnick Abstract Info/History Metrics Data/Code Preview PDF Abstract INTRODUCTION: Determining whether plasma biomarkers are preferentially associated with Alzheimer's disease (AD)-related rather than age-related brain atrophy patterns may clarify their prognostic and diagnostic clinical use. METHODS: Using data from the Baltimore Longitudinal Study of Aging (N=818), we examined cross-sectional plasma Aβ 42 /Aβ 40 , GFAP, NfL, p-tau181, and p-tau217 measurements obtained while participants were cognitively unimpaired (CU). During follow-up, 104 participants developed mild cognitive impairment (MCI)/dementia (74 due to AD, 24 due to non-AD, 6 unknown etiology). 2,293 longitudinal brain MRIs were used to quantify multidimensional atrophy pattern scores reflecting brain age (SPARE-BA), AD-like patterns (SPARE-AD), and five dominant dimensions of atrophy (R-indices). We investigated the associations of plasma biomarkers and atrophy pattern scores at index visit with conversion to MCI/dementia due to AD. We then examined the associations of plasma biomarkers with longitudinal change in pattern scores using linear mixed effects models. RESULTS: p-tau181, Aβ 42 /Aβ 40 (Lumipulse), and p-tau217 were associated with incident MCI/dementia due to AD but not non-AD etiologies, while GFAP was associated with incident MCI/dementia due to both AD and non-AD. All four biomarkers were associated with longitudinal SPARE-AD changes. Aβ 42 /Aβ 40 (Quanterix and Lumipulse), p-tau181, and p-tau217 were associated with longitudinal parieto-temporal atrophy. p-tau217 was the only biomarker associated with longitudinal medial temporal lobe atrophy. We did not find associations between plasma biomarkers and SPARE-BA or R-indices capturing subcortical, diffuse cortical, or perisylvian atrophy. DISCUSSION: Among CU individuals, plasma p-tau217 was associated with subsequent MCI/dementia due to AD and showed the most extensive associations with longitudinal AD-related brain atrophy. Competing Interest Statement K.A.W. is an Associate Editor for Alzheimer's & Dementia: The Journal of the Alzheimer's Association, Alzheimer's & Dementia: Translational Research and Clinical Interventions (TRCI), and on the Editorial Board of Annals of Clinical and Translational Neurology. K.A.W. is on the Board of Directors of the National Academy of Neuropsychology. K.A.W. has given unpaid presentations and seminars on behalf of SomaLogic. K.A.W. is the founder of Centia Bio. The work presented in this manuscript was conducted independently of Centia Bio and without financial support from the company. All efforts were performed in government research settings. The remaining authors have nothing to disclose. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: IRB of the National Institutes of Health gave ethical approval for this work. Research protocols were conducted in accordance with United States federal policy for the protection of human research subjects contained in Title 45 Part 46 of the Code of Federal Regulations (45 CFR 46), approved by the IRB of the National Institutes of Health, and all participants gave written informed consent at each visit. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability BLSA data are available upon request from https://www.blsa.nih.gov. Requests are reviewed by the Data Sharing Proposal Review Committee and require the establishment of a data transfer agreement between the NIA and the recipient institute. https://www.blsa.nih.gov Funder Information Declared Intramural Research Program of the National Institutes of Health (NIH) Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license. Back to top Previous Next Posted September 17, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Association of plasma biomarkers with longitudinal change in age- and Alzheimer's disease-related brain atrophy patterns Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Association of plasma biomarkers with longitudinal change in age- and Alzheimer's disease-related brain atrophy patterns Murat Bilgel , Ishaan Shah , Jasmine Cooper , Yang An , Keenan A Walker , Sara G Ho , Abhay R Moghekar , Zhijian Yang , Guray Erus , Christos Davatzikos , Luigi Ferrucci , Susan M Resnick medRxiv 2026.09.11.26362869; doi: https://doi.org/10.64898/2026.09.11.26362869 Share This Article: Copy Citation Tools Association of plasma biomarkers with longitudinal change in age- and Alzheimer's disease-related brain atrophy patterns Murat Bilgel , Ishaan Shah , Jasmine Cooper , Yang An , Keenan A Walker , Sara G Ho , Abhay R Moghekar , Zhijian Yang , Guray Erus , Christos Davatzikos , Luigi Ferrucci , Susan M Resnick medRxiv 2026.09.11.26362869; doi: https://doi.org/10.64898/2026.09.11.26362869 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (617) Allergy and Immunology (902) Anesthesia (334) Cardiovascular Medicine (4819) Dentistry and Oral Medicine (479) Dermatology (415) Emergency Medicine (650) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1629) Epidemiology (15955) Forensic Medicine (33) Gastroenterology (1203) Genetic and Genomic Medicine (7052) Geriatric Medicine (733) Health Economics (1065) Health Informatics (5052) Health Policy (1435) Health Systems and Quality Improvement (1768) Hematology (586) HIV/AIDS (1346) Infectious Diseases (except HIV/AIDS) (16298) Intensive Care and Critical Care Medicine (1173) Medical Education (669) Medical Ethics (155) Nephrology (725) Neurology (7282) Nursing (368) Nutrition (1082) Obstetrics and Gynecology (1241) Occupational and Environmental Health (1005) Oncology (3611) Ophthalmology (1054) Orthopedics (398) Otolaryngology (457) Pain Medicine (470) Palliative Medicine (139) Pathology (709) Pediatrics (1801) Pharmacology and Therapeutics (737) Primary Care Research (767) Psychiatry and Clinical Psychology (5906) Public and Global Health (9762) Radiology and Imaging (2427) Rehabilitation Medicine and Physical Therapy (1454) Respiratory Medicine (1249) Rheumatology (642) Sexual and Reproductive Health (772) Sports Medicine (578) Surgery (780) Toxicology (107) Transplantation (305) Urology (291)
## Related Clinical Research

- [Physiological variability in Alzheimer's biomarkers and the mechanistic basis for ratio normalizat](https://medichelpline.com/clinical-feed/medrxiv-7-physiological-variability-in-key-alzheimer-s-biomarkers-in-amyloid-positive.md)
- [Orexin agonist ALKS 7290 shows ADHD symptom improvement in early Phase 1 trial](https://medichelpline.com/clinical-feed/stat-news-0-stat-alkermes-orexin-agonist-shows-potential-to-treat-adhd-in-early-stage-trial.md)
- [Kennedy launches ARPA-H initiative to accelerate autism diagnoses and research](https://medichelpline.com/clinical-feed/stat-news-0-kennedy-announces-new-effort-to-speed-up-autism-diagnoses.md)
- [Antihypertensive Drug Class and Risk of Incident Alzheimer’s Disease and Related Dementias: Replic](https://medichelpline.com/clinical-feed/medrxiv-17-antihypertensive-medication-class-and-incident-alzheimers-disease-and-related.md)
- [Choroid Plexus Calcification in Lateral, Third, and Fourth Ventricles: Links to Aging, Brain Struc](https://medichelpline.com/clinical-feed/biorxiv-21-regional-choroid-plexus-calcifications-and-their-associations-with-aging-brain.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.